Robin K. Dore, MD, is a rheumatologitst practicing in Tustin, California and a Clinical Professor of Medicine, Division of Rheumatology at the David Geffen School of Medicine at the University of California, Los Angeles, CA.
Dr. Dore is a board-certified rheuma-tologist and she is also certified as a clinical densitometrist by the International Society for Clinical Densitometry.
Dr. Dore is immediate past Chair of the Southern California Chapter of the Arthritis Foundation. She has been president of the Southern California Rheumatology Society and a member of the board of directors of the American College of Rheumatology (ACR).
Dr. Dore led the development of the ACR Guidelines for Rheumatology Referral and recently served as an expert on the ACR panel for development of guidelines for use of biologics and DMARDs in rheumatoid arthritis.
She is recognized for her contributions to patient and physician education and community service, including the development of Bone Builders, a program devoted to educating girls and young women about the importance of healthy lifestyles in the prevention of osteoporosis.
A clinical investigator, Dr. Dore participates in research studies of medications for treatment of gout, osteoarthritis, osteoporosis, rheumatoid arthritis, and other diseases. She has investigated anti-TNF, anti-IL1, COX-2, RANK ligand inhibitor, selective estrogen receptor modulator, parathyroid hormone, and other agents.
Dr. Dore is a speaker and consultant for Amgen, Abbott Pharmaceuticals, Aventis, Eli Lilly and Company, McNeil, Merck and Co., Inc., Pfizer, Procter & Gamble, Wyeth Pharmaceuticals, and other pharmaceutical companies. Additionally, she receives grants from each.